Please login to the form below
Extavia
This page shows the latest Extavia news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding
to Novartis’ Extavia which had been the only recommended drug after a first cost appraisal.
Latest news
-
Novartis’ Extavia evades NICE restrictions on MS drugs
Multiple sclerosis patients in England and Wales look set to have just one interferon therapy option after draft NICE guidance backed routine funding for Novartis’ Extavia and rejected other drugs. ... The MS Society said the proposals won’t affect
-
Biogen Idec sues for patent infringement
Rebif generated global sales of $2.1bn in 2009, and Extavia achieved $20m in the first quarter. ... Novartis received approval last year to sell Extavia and currently pays royalties to Bayer.
-
FDA approves Extavia for MS
Extavia received EU approval in May 2008 to treat early and relapsing forms of MS. ... Extavia is reportedly the "first in a new planned portfolio" of MS medicines for Novartis.
-
Novartis gets MS drug approval
Novartis has announced that the European Commission has granted approval for its new multiple sclerosis (MS) treatment, Extavia, and has said it intends to continue broadening its product range in this ... Extavia is the same as the MS treatment Betaferon
Novartis’ Extavia evades NICE restrictions on MS drugs
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
INDIGENUS and Novartis MS
Indigenus presentation of the launch campaign rolled out for Extavia in Summer 2011.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital account director
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Events Executive
-
Depending on Experience
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital project manager
-
Competitive
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- Live Webinar: Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- Another Landmark Lucid Workiversary
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- EU approves bluebird bio’s CALD gene therapy Skysona
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- This month in 1939: How dead cattle led to the discovery of warfarin
- Recruiting patients for real-world studies – the power of a digital campaign
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
